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A multidisciplinary panel of physicians was convened by Network for Advancement of
Transfusion Alternatives to review the evidence on the efficacy and safety of i.v. iron adminis-
tration to increase haemoglobin levels and reduce blood transfusion in patients undergoing
surgery, and to develop a consensus statement on perioperative use of i.v. iron as a transfusion
alternative. After conducting a systematic literature search to identify the relevant studies, critical
evaluation of the evidence was performed and recommendations formulated using the Grades of
Recommendation Assessment, Development and Evaluation Working Group methodology. Two
randomized controlled trials (RCTs) and six observational studies in orthopaedic and cardiac
surgery were evaluated. Overall, there was little benefit found for the use of i.v. iron. At best, i.v.
iron supplementation was found to reduce the proportion of patients requiring transfusions and
the number of transfused units in observational studies in orthopaedic surgery but not in cardiac
surgery. The two RCTs had serious limitations and the six observational limited by the selection
of the control groups. Thus, the quality of the available evidence is considered moderate to very
low. For patients undergoing orthopaedic surgery and expected to develop severe postoperative
anaemia, the panel suggests i.v. iron administration during the perioperative period (weak
recommendation based on moderate/low-quality evidence). For all other types of surgery, no evi-
dence-based recommendation can be made. The panel recommends that large, prospective,
RCTs be undertaken to evaluate the efficacy and safety of i.v. iron administration in surgical
patients. The implementation of some general good practice points is suggested.
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Allogenic blood transfusion is commonly used to rapidly
and effectively increase haemoglobin levels and avoid the
deleterious effects of acute severe anaemia, especially in
elderly patients whose compensatory mechanisms may be
limited.5 However, although increasingly more safe, allo-
genic blood transfusion can never be risk-free, nor can
drugs and other interventions intended to reduce exposure
to donor blood. In addition, the impact of new illnesses and
infections on blood safety cannot be predicted.26 Thus, con-
cerns about adverse effects of allogenic blood transfusion
have prompted a review of transfusion practice, with
implementation of restrictive transfusion criteria, and the
search for a safer and more biologically rational treatment
of anaemia, such as pharmacological treatment, in order to
reduce patient risks and improve patient outcomes.22 26
Perioperative anaemia has been linked to increased post-
operative morbidity and mortality, and decreased quality
of life.35 Depending on the procedures and the definitions
of anaemia, from 11% to 76% of surgical patients may
present with preoperative anaemia,35 which is one of the
major predictive factors for allogenic blood transfusion
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related to surgery with moderate to high blood loss.12 13
The limited physiological reserve and the higher incidence
of unrecognized cardiovascular disease may make the
elderly population more vulnerable to milder degrees of
anaemia when undergoing surgery. In a retrospective
analysis of 310 311 patients aged 65 yr, who underwent
major non-cardiac surgery, it was found that the adjusted
risk of 30 day postoperative mortality and cardiac morbid-
ity started to increase when preoperative haematocrit
levels decreased below 39%.44 Anaemia may be due to
iron deficiency, chronic inflammation, or both. Folic acid
or vitamin B12 deficiencies may also be present, especially
in elderly patients.18
A recent retrospective observational study34 evaluating
the prevalence and characteristics of preoperative anaemia
in patients undergoing elective major joint arthroplasty in a
specialized Scottish orthopaedic hospital found that 224 of
1142 patients (19.6%) presented with preoperative anaemia
(defined as a haemoglobin concentration ,13 g dl21 in
males and ,11.5 g dl21 in females). The type of anaemia
was assessed based on mean cell volume and mean cell
haemoglobin. Of those with anaemia, 64.3% had normocy-
tic normochromic anaemia, consistent with the anaemia of
chronic disease, 23.3% had hypochromic anaemia, poten-
tially responsive to iron therapy alone, and 12.4% had
other types of anaemia. Overall, 21.3% of patients required
perioperative allogenic blood transfusion, compared with
42% of patients with preoperative anaemia.34
Postoperative anaemia, which may be present in up to
90% of patients undergoing major surgery,35 is mainly
caused by perioperative blood loss and may be aggravated
by blunting of erythropoiesis by inflammatory responses,
especially through decreased iron availability (i.e. hepci-
din-dependent down-regulation of intestinal absorption
and impaired mobilization from body stores).30 39 42 A
study of patients who had undergone hip arthroplasty
showed evidence of increased erythropoiesis by postopera-
tive day 7 and approximately two-thirds of the postopera-
tive haemoglobin deficit was corrected by day 28.40
However, in more than 25% of patients, the recovery of
haemoglobin levels was still incomplete on postoperative
day 56 and ferritin levels were significantly decreased in
patients who were not transfused. The authors concluded
that this was mainly due to functional or (more frequently)
true iron deficiency; the main predictors for postoperative
iron deficiency are perioperative blood loss and preopera-
tive iron stores.
The currently available evidence does not support the
efficacy of postoperative oral iron supplementation: in five
randomized controlled trials (RCTs) (four after orthopae-
dic surgery and one after cardiac surgery), postoperative
administration of oral iron failed to increase haemoglobin
levels.7 29 37 41 45 It has been suggested that both minor
and major surgery induce distinctive changes in iron
metabolism, similar to those observed in the anaemia of
chronic disease, which may explain the ineffectiveness of
oral iron supplementation during the postoperative
period.39 In contrast, preoperative oral iron supplemen-
tation in patients undergoing colorectal resection was
found to increase haemoglobin levels immediately before
surgery and to reduce the proportion of patients requiring
intraoperative allogenic blood transfusions in comparison
with a control group (9.4% vs 27.4%, P,0.05).33
However, there were no significant differences in post-
operative haemoglobin levels or volume transfused
between the two groups.33 A recent prospective RCT in
patients undergoing elective colorectal resections showed
that preoperative oral iron therapy (with a median length
of treatment of 14 days) significantly reduced the number
of patients requiring red blood cell transfusions from 59%
to 26% (P¼0.031).23 In an RCT of patients undergoing
orthopaedic surgery, preoperative oral iron administration
was found to prevent postoperative decreases in haemo-
globin levels,1 and oral iron combined with a restrictive
transfusion protocol was associated with a reduction in
transfusion requirements in an observational study.11
Although oral administration is the conventional route
for iron because of its convenience and low cost, i.v. iron
has emerged as a safe and effective alternative for peri-
operative anaemia management. This takes into consider-
ation factors such as intolerance of or contraindications to
oral iron (e.g. inflammatory bowel disease), short time to
surgery, severe preoperative anaemia, or the use of
erythropoiesis-stimulating agents.
Methods
A multidisciplinary panel of physicians with expertise and
experience in perioperative anaemia management was con-
vened by the Network for Advancement of Transfusion
Alternatives (NATA), in January 2007, in Barcelona,
Spain. The panel’s aim was to review the available evi-
dence on i.v. iron administration as a means of increasing
haemoglobin levels and reducing the need for allogenic
blood transfusion in patients undergoing surgery. Its goal
was also to develop a consensus statement on perioperative
use of i.v. iron as an alternative to blood transfusion
(Table 1). The use of i.v. iron in the settings of preopera-
tive autologous blood donation and preoperative adminis-
tration of recombinant human erythropoietin (rHuEPO) or
other alternatives to allogenic blood transfusion were
included in the discussion. The Medline database was
searched using the MESH keywords ‘anemia’, ‘surgery’,
‘iron’, and ‘blood transfusion’, and the abstracts of the
retrieved references were reviewed to identify the studies
with at least one patient group given i.v. iron alone for
the treatment of perioperative anaemia. The search
was restricted to English- and French-language articles.
A critical evaluation of the evidence was then performed
and recommendations were formulated according to the
method proposed by the Grades of Recommendation
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Assessment, Development and Evaluation (GRADE)
Working Group (Table 2).3
The evidence base
Summary of relevant evidence
A more detailed analysis of the studies can be found in the
Appendix, online at http:///www.bja.oxfordjournals.org.uk.
Preoperative
There were two observational studies with control groups
in patients undergoing hip fracture repair.8 9 In patients
with hip fracture who were operated on 2–4 days after
admission, preoperative use of i.v. iron alone (2–3100 mg,
starting on admission) was effective in reducing the
transfusion rate when compared with historical control
patients.8 9 In addition, there was a significant reduction in
the postoperative infection rate and in hospital stay and 30
day postoperative mortality.9
Perioperative
In one observational study, perioperative i.v. iron adminis-
tration (3200 mg in 48 h, starting on admission), alone
or in combination with a single-dose rHuEPO (40 000 IU
on admission) if preoperative haemoglobin concentration
was ,13 g dl21, plus a restrictive transfusion trigger
(8 g dl21), reduced allogenic blood transfusion in hip
fracture patients who underwent surgery 2–6 days after
admission.14 There was also a significant reduction in the
postoperative infection rate.14 In addition, a similar proto-
col reduced the proportion of patients requiring allogenic
blood transfusions (,5%) in total knee replacement, in
comparison with a previous series from the same insti-
tution in which the transfusion rate was 30%.10
Postoperative
There were two prospective, randomized trials21 25 and
three observational studies with control groups.4 20 32
RCTs: in cardiac surgery patients and in a small group of
orthopaedic patients, postoperative administration of i.v.
iron, alone or in combination with rHuEPO, was not
associated with a greater increase in haemoglobin concen-
tration than placebo.4 25 Similar results were obtained in
one of the observational studies in cardiac surgery
patients.32 In contrast, in one observational study of ortho-
paedic patients, i.v. iron resulted in higher haemoglobin
concentrations compared with oral iron.20 In the third
observational study, postoperative administration of i.v.
iron (3100 mg per day, starting on the first postoperative
day) in patients undergoing total hip replacement resulted
in a reduction in the transfusion rate and volume compared
with a historical control group.6
Safety
Although no serious life-threatening adverse events or
increment in postoperative infection rate were reported, the
number of patients included in these studies is not large
enough to draw definitive conclusions regarding the safety
of i.v. iron agents. However, data from the US Food and
Drug Administration suggest that the total number of
reported parenteral iron-related adverse drug events (ADEs)
was 1141 from approximately 30 million doses given
(approximately 38 ADEs per million).36 The rates of life-
threatening events were 0.6, 0.9, 3.3, and 11.3 per million
for iron sucrose, sodium ferric gluconate complex, low-
molecular-weight iron dextran, and high-molecular-weight
iron dextran, respectively, and the death rates were 0.11,
0.25, 0.75, and 0.78 per million, respectively.36 Therefore,
the rates of life-threatening ADEs associated with iron (2.2
per million), including iron-related deaths (0.4 per million),
are lower than those of transfusion-related severe side-
effects (10 per million) and transfusion-related deaths (4
per million).19 36 In addition, several studies suggested that
previously observed associations between iron adminis-
tration and higher infection and mortality rates may have
been due to confounding variables.28 38
Quality of evidence
Of the studies evaluating the efficacy of i.v. iron to reduce
perioperative allogenic blood transfusion, the two RCTs
have serious limitations (small number of patients, ran-
domization bias, inconsistency, etc.), whereas the six
Table 2 Criteria for assigning grade of evidence according to the GRADE
Working Group3
Levels of evidence: high, moderate, low, and very low
Types of evidence
Randomized controlled trial, high
Observational study, low
Any other evidence, very low
Decrease grade if
Serious (21) or very serious (22) limitation to study quality
Important inconsistency (21)
Some (21) or major (22) uncertainty about directness
Imprecise or sparse data (21)
High probability of reporting bias (21)
Increase grade if
Strong evidence of association—significant relative risk of .2 (,0.5)
based on consistent evidence from two or more observational studies, with no
plausible confounders (þ1)
Very strong evidence of association—significant relative risk of .5 (,0.2)
based on direct evidence with no major threats to validity (þ2)
Evidence of a dose–response gradient (þ1)
All plausible confounders would have reduced the effect (þ1)
Table 1 Summary of expert panel’s remit
Target population Patients undergoing surgery and expected to develop
severe postoperative anaemia requiring allogenic blood
transfusion
Question How to increase haemoglobin in the perioperative period?
Proposed
intervention
Administration of i.v. iron
Relevant outcome Reduction in the perioperative transfusion rate and the
volume of blood transfused
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observational studies appear to have been well conducted,
but are limited by the selection of the control groups.
Thus, the level of evidence is considered moderate,4 low,6
8 10 14 25 32 and very low.20
Best estimates
Pre- and perioperative i.v. iron administration may reduce
both the proportion of patients requiring blood transfusions
and the volume of blood transfused.
Judgement of benefits vs risks, burden, and cost
The available information suggests benefits of pre- and
perioperative i.v. iron administration, especially for
patients with anaemia, but the quality of evidence is low.
Recommendation
For patients undergoing elective and non-elective ortho-
paedic surgery and expected to develop severe postopera-
tive anaemia, we currently suggest i.v. iron administration
during the perioperative period. This is a weak recommen-
dation based on moderate- and low-quality evidence. For
all other surgeries, no evidence-based recommendation
can be made.
We strongly recommend that large, prospective, RCTs
be undertaken in surgical patients expected to develop
severe postoperative anaemia.
General good practice points
In addition to the recommendations stated above, the fol-
lowing points based on the experience of the panel
members can be considered good clinical practice for sur-
gical patients.
† Patients at risk of receiving perioperative transfusions
should be identified based on the patient’s red blood
cell mass, the transfusion trigger, and the expected
blood loss, for example, using Mercuriali’s algorithm.28
† Whenever clinically feasible, patients undergoing elec-
tive surgery with a high risk of severe postoperative
anaemia should have their haemoglobin concentration15
and iron status (serum iron, serum ferritin, transferrin
saturation, and C-reactive protein) tested, preferably at
least 30 days before the scheduled surgical procedure.
For patients .60 yr old, vitamin B12 and folic acid
should also be measured.18
† Patients with preoperative anaemia due to iron deficiency
or chronic disease may receive preoperative treatment
with oral or i.v. iron, depending on the timescale before
surgery, tolerance of oral iron, and iron status.15 In
addition, i.v. iron rather than oral iron should be given to
improve response to rHuEPO and might allow for a
reduction in rHuEPO dose requirements.2 16 21 31 Total
i.v. iron dose (TID) can be calculated according to the
formula: TID (mg)¼(Hbtarget–Hbactual) (g dl21)weight
(kg)2.4. After operation, 150 mg of i.v. iron per g dl21
of haemoglobin drop should be added to compensate
iron loss due to perioperative bleeding.
† Unexplained anaemia should always be considered as
secondary to some other process and, therefore, elective
surgery, especially for non-malignant disease, should be
deferred if possible until the anaemia is adequately
evaluated and treated.17
† Non-anaemic patients with a serum ferritin level ,100
ng ml21 (or ferritin 100–300 ng ml21 and transferrin
saturation ,20%) undergoing surgical procedures with
an expected blood loss .1500 ml (haemoglobin drop of
3–5 g dl21) may benefit from preoperative oral or i.v.
iron administration, depending on the presence of
co-morbidities and on the timescale before surgery, as
they may not have enough stored iron to replenish their
perioperative haemoglobin loss and maintain normal
iron stores (serum ferritin 30 ng ml21).3 7 11 40
† Administration of i.v. iron should be avoided in patients
with pre-treatment ferritin values .300–500 ng ml21
and transferrin saturation .50%.24 Moreover, despite
the absence of definitive clinical data, as all i.v. iron
agents have the potential to release biologically active
iron, it seems reasonable to avoid i.v. iron adminis-
tration in the setting of acute infection.43
† Finally, it must be borne in mind that the goal of per-
forming major surgical procedures without the use of
allogenic blood transfusion and without placing the
patient at risk for anaemia-related complications may be
better accomplished by combining several blood-saving
techniques into a defined algorithm such as those pro-
posed recently27 43 in orthopaedic surgery.
Conclusion
A recommendation on the perioperative use of i.v. iron to
increase haemoglobin levels and reduce allogenic blood
transfusion can only be made for orthopaedic surgical
patients based on moderate- to low-quality evidence.
Therefore, the panel strongly recommends that large, pro-
spective, RCTs be undertaken in patients expected to
develop severe postoperative anaemia before routine use of
i.v. iron can be recommended. The outcomes to be evalu-
ated in such studies should also include length of hospital
stay, postoperative morbidity and mortality, postoperative
recovery, costs, etc. Meanwhile, the implementation of the
suggested good clinical practice points is proposed.
Supplementary material
Supplementary material is available at British Journal of
Anaesthesia online.
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